首页 > 最新文献

Journal of Infection and Public Health最新文献

英文 中文
Antibiotic resistance pattern of waterborne causative agents of healthcare-associated infections: A call for biofilm control in hospital water systems 医疗相关感染的水源致病菌的抗生素耐药性模式:呼吁控制医院供水系统中的生物膜
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jiph.2024.102469
Sahar Gholipour , Mahnaz Nikaeen , Farzaneh Mohammadi , Davarkhah Rabbani

Background

In recent years, the global spread of antimicrobial resistance has become a concerning issue, often referred to as a “silent pandemic”. Healthcare-associated infections (HAIs) caused by antibiotic-resistant bacteria (ARB) are a recurring problem, with some originating from waterborne route. The study aimed to investigate the presence of clinically relevant opportunistic bacteria and antibiotic resistance genes (ARGs) in hospital water distribution systems (WDSs).

Methods

Water and biofilm samples (n = 192) were collected from nine hospitals in Isfahan and Kashan, located in central Iran, between May 2022 and June 2023. The samples were analyzed to determine the presence and quantities of opportunistic bacteria and ARGs using cultural and molecular methods.

Results

Staphylococcus spp. were highly detected in WDS samples (90 isolates), with 33 % of them harboring mecA gene. However, the occurrences of E. coli (1 isolate), Acinetobacter baumannii (3 isolates), and Pseudomonas aeruginosa (14 isolates) were low. Moreover, several Gram-negative bacteria containing ARGs were identified in the samples, mainly belonging to Stenotrophomonas, Sphingomonas and Brevundimonas genera. Various ARGs, as well as intI1, were found in hospital WDSs (ranging from 14 % to 60 %), with higher occurrences in the biofilm samples.

Conclusion

Our results underscore the importance of biofilms in water taps as hotspots for the dissemination of opportunistic bacteria and ARG within hospital environments. The identification of multiple opportunistic bacteria and ARGs raises concerns about the potential exposure and acquisition of HAIs, emphasizing the need for proactive measures, particularly in controlling biofilms, to mitigate infection risks in healthcare settings.

背景近年来,抗菌药耐药性在全球的蔓延已成为一个令人担忧的问题,通常被称为 "无声的流行病"。耐抗生素细菌(ARB)引起的医疗相关感染(HAIs)是一个经常出现的问题,其中一些感染源于水传播途径。本研究旨在调查医院配水系统 (WDS) 中是否存在临床相关的机会性细菌和抗生素耐药基因 (ARG)。方法在 2022 年 5 月至 2023 年 6 月期间,从位于伊朗中部伊斯法罕和卡尚的九家医院收集了水和生物膜样本(n = 192)。结果在 WDS 样本中高度检测到葡萄球菌属(90 个分离株),其中 33% 携带 mecA 基因。然而,大肠杆菌(1 株)、鲍曼不动杆菌(3 株)和铜绿假单胞菌(14 株)的检出率较低。此外,样本中还发现了几种含有 ARGs 的革兰氏阴性细菌,主要属于 Stenotrophomonas、Sphingomonas 和 Brevundimonas 属。我们的研究结果表明,水龙头中的生物膜是机会性细菌和 ARG 在医院环境中传播的热点。多种机会性细菌和 ARGs 的发现引起了人们对潜在的 HAIs 暴露和感染的关注,强调了采取积极措施的必要性,尤其是在控制生物膜方面,以降低医疗环境中的感染风险。
{"title":"Antibiotic resistance pattern of waterborne causative agents of healthcare-associated infections: A call for biofilm control in hospital water systems","authors":"Sahar Gholipour ,&nbsp;Mahnaz Nikaeen ,&nbsp;Farzaneh Mohammadi ,&nbsp;Davarkhah Rabbani","doi":"10.1016/j.jiph.2024.102469","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.102469","url":null,"abstract":"<div><h3>Background</h3><p>In recent years, the global spread of antimicrobial resistance has become a concerning issue, often referred to as a “silent pandemic”. Healthcare-associated infections (HAIs) caused by antibiotic-resistant bacteria (ARB) are a recurring problem, with some originating from waterborne route. The study aimed to investigate the presence of clinically relevant opportunistic bacteria and antibiotic resistance genes (ARGs) in hospital water distribution systems (WDSs).</p></div><div><h3>Methods</h3><p>Water and biofilm samples (n = 192) were collected from nine hospitals in Isfahan and Kashan, located in central Iran, between May 2022 and June 2023. The samples were analyzed to determine the presence and quantities of opportunistic bacteria and ARGs using cultural and molecular methods.</p></div><div><h3>Results</h3><p><em>Staphylococcus</em> spp. were highly detected in WDS samples (90 isolates), with 33 % of them harboring <em>mec</em>A gene. However, the occurrences of <em>E. coli</em> (1 isolate), <em>Acinetobacter baumannii</em> (3 isolates), and <em>Pseudomonas aeruginosa</em> (14 isolates) were low. Moreover, several Gram-negative bacteria containing ARGs were identified in the samples, mainly belonging to <em>Stenotrophomonas</em>, <em>Sphingomonas</em> and <em>Brevundimonas</em> genera. Various ARGs, as well as <em>intI</em>1, were found in hospital WDSs (ranging from 14 % to 60 %), with higher occurrences in the biofilm samples.</p></div><div><h3>Conclusion</h3><p>Our results underscore the importance of biofilms in water taps as hotspots for the dissemination of opportunistic bacteria and ARG within hospital environments. The identification of multiple opportunistic bacteria and ARGs raises concerns about the potential exposure and acquisition of HAIs, emphasizing the need for proactive measures, particularly in controlling biofilms, to mitigate infection risks in healthcare settings.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187603412400203X/pdfft?md5=2ce01e0d054103560738237fa2cffd0b&pid=1-s2.0-S187603412400203X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141244987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer COVID-19口服抗病毒疗法在管理非住院肺癌患者中的效果
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jiph.2024.05.053
Wan-Hsuan Hsu , Bo-Wen Shiau , Ya-Wen Tsai , Jheng-Yan Wu , Po-Yu Huang , Min-Hsiang Chuang , Ting-Hui Liu , Chih-Cheng Lai , Tzu-Chieh Weng

Backgrounds

The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of COVID-19 among patients with lung cancer.

Methods

Utilizing data from the TriNetX – a global health research network, a retrospective cohort study was conducted involving 2484 patients diagnosed with both lung cancer and COVID-19. Propensity score matching (PSM) was employed to create well-balanced cohorts. The study assessed the primary outcome of all-cause hospitalization or mortality within a 30-day follow-up.

Results

After PSM, the oral antiviral group exhibited a significantly lower risk of the primary composite outcome compared to the control group (6.1 % vs. 9.9 %; HR: 0.60; 95 % CI: 0.45–0.80). This association was consistent across various subgroups according to age, sex, vaccine status, type of oral antiviral agent, and lung cancer characteristics. Additionally, the oral antiviral group showed a lower risk of all-cause hospitalization (HR: 0.73; 95 % CI: 0.54–0.99) and a significantly lower risk of mortality (HR: 0.16; 95 % CI: 0.06–0.41).

Conclusion

The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population.

背景包括尼尔马特韦加利托那韦和莫仑吡韦在内的口服抗病毒疗法在治疗已患肺癌的 COVID-19 患者中的效果尚不明确。因此,本研究旨在评估抗病毒药物在肺癌患者COVID-19治疗中的作用。方法利用全球健康研究网络TriNetX的数据,开展了一项回顾性队列研究,涉及2484名同时被诊断为肺癌和COVID-19的患者。研究采用倾向得分匹配法(PSM)创建了平衡良好的队列。研究评估了随访 30 天内全因住院或死亡的主要结局。结果在 PSM 后,与对照组相比,口服抗病毒药物组的主要综合结局风险显著降低(6.1% 对 9.9%;HR:0.60;95 % CI:0.45-0.80)。根据年龄、性别、疫苗接种情况、口服抗病毒药物类型和肺癌特征,这种关联在不同的亚组中是一致的。此外,口服抗病毒药物组显示出较低的全因住院风险(HR:0.73;95 % CI:0.54-0.99)和显著较低的死亡风险(HR:0.16;95 % CI:0.06-0.41)。
{"title":"The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer","authors":"Wan-Hsuan Hsu ,&nbsp;Bo-Wen Shiau ,&nbsp;Ya-Wen Tsai ,&nbsp;Jheng-Yan Wu ,&nbsp;Po-Yu Huang ,&nbsp;Min-Hsiang Chuang ,&nbsp;Ting-Hui Liu ,&nbsp;Chih-Cheng Lai ,&nbsp;Tzu-Chieh Weng","doi":"10.1016/j.jiph.2024.05.053","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.05.053","url":null,"abstract":"<div><h3>Backgrounds</h3><p>The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of COVID-19 among patients with lung cancer.</p></div><div><h3>Methods</h3><p>Utilizing data from the TriNetX – a global health research network, a retrospective cohort study was conducted involving 2484 patients diagnosed with both lung cancer and COVID-19. Propensity score matching (PSM) was employed to create well-balanced cohorts. The study assessed the primary outcome of all-cause hospitalization or mortality within a 30-day follow-up.</p></div><div><h3>Results</h3><p>After PSM, the oral antiviral group exhibited a significantly lower risk of the primary composite outcome compared to the control group (6.1 % vs. 9.9 %; HR: 0.60; 95 % CI: 0.45–0.80). This association was consistent across various subgroups according to age, sex, vaccine status, type of oral antiviral agent, and lung cancer characteristics. Additionally, the oral antiviral group showed a lower risk of all-cause hospitalization (HR: 0.73; 95 % CI: 0.54–0.99) and a significantly lower risk of mortality (HR: 0.16; 95 % CI: 0.06–0.41).</p></div><div><h3>Conclusion</h3><p>The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001989/pdfft?md5=1f594ba33955e8e50e639c64fed79612&pid=1-s2.0-S1876034124001989-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alzheimer's disease risk associated with changes in Epstein-Barr virus nuclear antigen 1-specific epitope targeting antibody levels 阿尔茨海默病风险与 Epstein-Barr 病毒核抗原 1 特异性表位靶向抗体水平的变化有关。
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jiph.2024.05.050
Kyu-Young Sim , Jaekyeung An , So-Eun Bae , Taewoo Yang , Gwang-Hoon Ko , Jeong-Ryul Hwang , Kyu Yeong Choi , Jung Eun Park , Jung Sup Lee , Byeong C. Kim , Kun Ho Lee , Sung-Gyoo Park

Background

Alzheimer's disease (AD) is a neurodegenerative disorder influenced by age, sex, genetic factors, immune alterations, and infections. Multiple lines of evidence suggest that changes in antibody response are linked to AD pathology.

Methods

To elucidate the mechanisms underlying AD development, we investigated antibodies that target autoimmune epitopes using high-resolution epitope microarrays. Our study compared two groups: individuals with AD (n = 19) and non-demented (ND) controls (n = 19). To validate the results, we measured antibody levels in plasma samples from AD patients (n = 96), mild cognitive impairment (MCI; n = 91), and ND controls (n = 97). To further explore the invlovement of EBV, we performed epitope masking immunofluorescence microscopy analysis and tests to induce lytic replication using the B95–8 cell line.

Results

In this study, we analyzed high-resolution epitope-specific serum antibody levels in AD, revealing significant disparities in antibodies targeting multiple epitopes between the AD and control groups. Particularly noteworthy was the significant down-regulation of antibody (anti-DG#29) targeting an epitope of Epstein-Barr virus nuclear antigen 1 (EBNA1). This down-regulation increased AD risk in female patients (odds ratio up to 6.6), but not in male patients. Our investigation further revealed that the down-regulation of the antibody (anti-DG#29) is associated with EBV reactivation in AD, as indicated by the analysis of EBV VCA IgG or IgM levels. Additionally, our data demonstrated that the epitope region on EBNA1 for the antibody is hidden during the EBV lytic reactivation of B95–8 cells.

Conclusion

Our findings suggest a potential relationship of EBV in the development of AD in female. Moreover, we propose that antibodies targeting the epitope (DG#29) of EBNA1 could serve as valuable indicators of AD risk in female.

背景:阿尔茨海默病(AD)是一种神经退行性疾病,受年龄、性别、遗传因素、免疫改变和感染的影响。多种证据表明,抗体反应的变化与阿尔茨海默病的病理变化有关:为了阐明阿德发病的机制,我们使用高分辨率表位芯片研究了针对自身免疫表位的抗体。我们的研究比较了两组人群:AD 患者(19 人)和非痴呆(ND)对照组(19 人)。为了验证研究结果,我们测量了 AD 患者(n = 96)、轻度认知障碍(MCI;n = 91)和 ND 对照组(n = 97)血浆样本中的抗体水平。为了进一步探索EB病毒的侵袭,我们进行了表位掩蔽免疫荧光显微镜分析,并使用B95-8细胞系进行了诱导溶解复制的测试:在这项研究中,我们分析了AD患者的高分辨率表位特异性血清抗体水平,发现AD组和对照组之间针对多个表位的抗体水平存在显著差异。尤其值得注意的是,针对 Epstein-Barr 病毒核抗原 1 (EBNA1) 表位的抗体(抗 DG#29)出现了明显的下调。这种下调增加了女性患者的 AD 风险(几率比高达 6.6),而男性患者则没有。我们的研究进一步发现,抗体(抗 DG#29)的下调与 AD 中的 EBV 再激活有关,这一点可以通过分析 EBV VCA IgG 或 IgM 水平来证明。此外,我们的数据还表明,在B95-8细胞的EBV溶解性再活化过程中,抗体在EBNA1上的表位区被隐藏起来:结论:我们的研究结果表明,EB病毒与女性注意力缺失症的发病有潜在关系。此外,我们还提出,针对 EBNA1 表位(DG#29)的抗体可作为女性 AD 风险的重要指标。
{"title":"Alzheimer's disease risk associated with changes in Epstein-Barr virus nuclear antigen 1-specific epitope targeting antibody levels","authors":"Kyu-Young Sim ,&nbsp;Jaekyeung An ,&nbsp;So-Eun Bae ,&nbsp;Taewoo Yang ,&nbsp;Gwang-Hoon Ko ,&nbsp;Jeong-Ryul Hwang ,&nbsp;Kyu Yeong Choi ,&nbsp;Jung Eun Park ,&nbsp;Jung Sup Lee ,&nbsp;Byeong C. Kim ,&nbsp;Kun Ho Lee ,&nbsp;Sung-Gyoo Park","doi":"10.1016/j.jiph.2024.05.050","DOIUrl":"10.1016/j.jiph.2024.05.050","url":null,"abstract":"<div><h3>Background</h3><p>Alzheimer's disease (AD) is a neurodegenerative disorder influenced by age, sex, genetic factors, immune alterations, and infections. Multiple lines of evidence suggest that changes in antibody response are linked to AD pathology.</p></div><div><h3>Methods</h3><p>To elucidate the mechanisms underlying AD development, we investigated antibodies that target autoimmune epitopes using high-resolution epitope microarrays. Our study compared two groups: individuals with AD (n = 19) and non-demented (ND) controls (n = 19). To validate the results, we measured antibody levels in plasma samples from AD patients (n = 96), mild cognitive impairment (MCI; n = 91), and ND controls (n = 97). To further explore the invlovement of EBV, we performed epitope masking immunofluorescence microscopy analysis and tests to induce lytic replication using the B95–8 cell line.</p></div><div><h3>Results</h3><p>In this study, we analyzed high-resolution epitope-specific serum antibody levels in AD, revealing significant disparities in antibodies targeting multiple epitopes between the AD and control groups. Particularly noteworthy was the significant down-regulation of antibody (anti-DG#29) targeting an epitope of Epstein-Barr virus nuclear antigen 1 (EBNA1). This down-regulation increased AD risk in female patients (odds ratio up to 6.6), but not in male patients. Our investigation further revealed that the down-regulation of the antibody (anti-DG#29) is associated with EBV reactivation in AD, as indicated by the analysis of EBV VCA IgG or IgM levels. Additionally, our data demonstrated that the epitope region on EBNA1 for the antibody is hidden during the EBV lytic reactivation of B95–8 cells.</p></div><div><h3>Conclusion</h3><p>Our findings suggest a potential relationship of EBV in the development of AD in female. Moreover, we propose that antibodies targeting the epitope (DG#29) of EBNA1 could serve as valuable indicators of AD risk in female.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001953/pdfft?md5=8c6e6495bc835fba222707bfdc405a5a&pid=1-s2.0-S1876034124001953-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial resistance among pregnant women with urinary tract infections is on rise: Findings from meta-analysis of observational studies 尿路感染孕妇的抗菌药耐药性正在上升:观察性研究的荟萃分析结果
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-31 DOI: 10.1016/j.jiph.2024.05.055
Hanan M. Al Kadri , Ashraf A. El-Metwally , Atika A. Al Sudairy , Raed A. Al-Dahash , Badr F. Al Khateeb , Sameera M. Al Johani

Pregnant women have a higher risk of urinary tract infections (UTIs) compared to non-pregnant women, making antibiotics necessary for treatment. However, prescribing antibiotics without culture and sensitivity tests may contribute to antimicrobial resistance. A meta-analysis using R was conducted to determine the prevalence of antibiotic resistance patterns in UTIs among pregnant women. We identified observational studies published in the last 10 years and used a random effects model to calculate the pooled prevalence. The prevalence of Gram-negative organisms causing UTIs in pregnant women was 67 %, while Gram-positive organisms were 22 %. The burden of Gram-positive organisms exhibiting antimicrobial resistance was very high at 95 %, primarily to ampicillin. The most common Gram-negative organisms exhibiting antimicrobial resistance were E. coli, Klebsiella, and Pseudomonas aeruginosa, while the most common Gram-positive organisms resistant to antibiotics were Staphylococcus aureus and coagulase-negative Staphylococcus. Sensitivity and culture testing are recommended for effective treatment in pregnant women with UTIs.

与非孕妇相比,孕妇患尿路感染(UTI)的风险更高,因此必须使用抗生素进行治疗。然而,不经培养和药敏试验就开具抗生素处方可能会导致抗菌药耐药性。我们使用 R 进行了一项荟萃分析,以确定孕妇UTI 中抗生素耐药性模式的流行情况。我们确定了过去 10 年中发表的观察性研究,并使用随机效应模型计算了汇总的流行率。导致孕妇UTI的革兰氏阴性菌的流行率为67%,而革兰氏阳性菌为22%。表现出抗菌药耐药性的革兰氏阳性菌比例高达 95%,主要是对氨苄西林。最常见的耐药性革兰氏阴性菌是大肠杆菌、克雷伯氏菌和铜绿假单胞菌,而最常见的耐药性革兰氏阳性菌是金黄色葡萄球菌和凝固酶阴性葡萄球菌。建议对患有尿道炎的孕妇进行药敏试验和培养试验,以便进行有效治疗。
{"title":"Antimicrobial resistance among pregnant women with urinary tract infections is on rise: Findings from meta-analysis of observational studies","authors":"Hanan M. Al Kadri ,&nbsp;Ashraf A. El-Metwally ,&nbsp;Atika A. Al Sudairy ,&nbsp;Raed A. Al-Dahash ,&nbsp;Badr F. Al Khateeb ,&nbsp;Sameera M. Al Johani","doi":"10.1016/j.jiph.2024.05.055","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.05.055","url":null,"abstract":"<div><p>Pregnant women have a higher risk of urinary tract infections (UTIs) compared to non-pregnant women, making antibiotics necessary for treatment. However, prescribing antibiotics without culture and sensitivity tests may contribute to antimicrobial resistance. A meta-analysis using R was conducted to determine the prevalence of antibiotic resistance patterns in UTIs among pregnant women. We identified observational studies published in the last 10 years and used a random effects model to calculate the pooled prevalence. The prevalence of Gram-negative organisms causing UTIs in pregnant women was 67 %, while Gram-positive organisms were 22 %. The burden of Gram-positive organisms exhibiting antimicrobial resistance was very high at 95 %, primarily to ampicillin. The most common Gram-negative organisms exhibiting antimicrobial resistance were E. coli, Klebsiella, and Pseudomonas aeruginosa, while the most common Gram-positive organisms resistant to antibiotics were Staphylococcus aureus and coagulase-negative Staphylococcus. Sensitivity and culture testing are recommended for effective treatment in pregnant women with UTIs.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124002004/pdfft?md5=338b63de2483f5b1c87f4ed4618bbd7a&pid=1-s2.0-S1876034124002004-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141290330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful treatment of invasive mycobacterium infection with interferon beta in a patient with Interferon-Gamma Receptor 1 deficiency 干扰素-γ受体 1 缺乏症患者使用干扰素 beta 成功治疗侵袭性分枝杆菌感染
IF 4.7 3区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-05-31 DOI: 10.1016/j.jiph.2024.102468
Fayhan Alroqi , Abduarahman Almutairi , Moza Alhammadi , Shatha Alhamdi

Mendelian susceptibility to mycobacterial disease (MSMD) is caused by approximately 21 genetic defects, including a mutation in Interferon-Gamma Receptor 1 (IFNGR1). IFNGR1 deficiency leads to a loss of cellular responsiveness to type II Interferon (IFN-γ), which plays a significant role in controlling intracellular bacteria. This study explored the response of IFN–β therapy in a patient with partial IFNGR1 deficiency to treat invasive mycobacterial infection. The biological therapy was used successfully as an adjuvant to anti-mycobacterial medications to treat a 17-year-old girl with partial IFNGR1 deficiency who presented with a recurrent mycobacterial infection that extended to her central nervous system, which resulted in clinical and radiological improvement. This report suggests that activation of type I IFN through Signal Transducers and Activators of Transcription1 (STAT1) could bypass the early IFN-γ signaling defects and activate IFN-γ production. For that reason, IFN–β might be used as a beneficial adjuvant therapy for managing extensive central nervous system mycobacterial infection, especially in patients with IFNGR1 deficiency.

孟德尔分枝杆菌病(MSMD)易感性由大约 21 种遗传缺陷引起,其中包括干扰素-γ 受体 1(IFNGR1)的突变。IFNGR1 缺乏会导致细胞对 II 型干扰素(IFN-γ)失去反应能力,而 II 型干扰素在控制细胞内细菌方面发挥着重要作用。本研究探讨了 IFN-β 疗法对部分 IFNGR1 缺乏症患者治疗侵袭性霉菌感染的反应。该生物疗法作为抗霉菌药物的辅助疗法,成功地治疗了一名患有部分 IFNGR1 缺乏症的 17 岁女孩,她的霉菌感染反复发作,并扩展到中枢神经系统,结果临床和放射学症状均有所改善。该报告表明,通过信号转导和转录激活因子1(STAT1)激活I型IFN可绕过早期IFN-γ信号缺陷,激活IFN-γ的产生。因此,IFN-β 可作为一种有益的辅助疗法,用于治疗广泛的中枢神经系统分枝杆菌感染,尤其是 IFNGR1 缺乏症患者。
{"title":"Successful treatment of invasive mycobacterium infection with interferon beta in a patient with Interferon-Gamma Receptor 1 deficiency","authors":"Fayhan Alroqi ,&nbsp;Abduarahman Almutairi ,&nbsp;Moza Alhammadi ,&nbsp;Shatha Alhamdi","doi":"10.1016/j.jiph.2024.102468","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.102468","url":null,"abstract":"<div><p>Mendelian susceptibility to mycobacterial disease (MSMD) is caused by approximately 21 genetic defects, including a mutation in Interferon-Gamma Receptor 1 (IFNGR1). IFNGR1 deficiency leads to a loss of cellular responsiveness to type II Interferon (IFN-γ), which plays a significant role in controlling intracellular bacteria. This study explored the response of IFN–β therapy in a patient with partial IFNGR1 deficiency to treat invasive mycobacterial infection. The biological therapy was used successfully as an adjuvant to anti-mycobacterial medications to treat a 17-year-old girl with partial IFNGR1 deficiency who presented with a recurrent mycobacterial infection that extended to her central nervous system, which resulted in clinical and radiological improvement. This report suggests that activation of type I IFN through Signal Transducers and Activators of Transcription1 (STAT1) could bypass the early IFN-γ signaling defects and activate IFN-γ production. For that reason, IFN–β might be used as a beneficial adjuvant therapy for managing extensive central nervous system mycobacterial infection, especially in patients with IFNGR1 deficiency.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124002028/pdfft?md5=44010a7a998a778c7015314b49742bf4&pid=1-s2.0-S1876034124002028-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phenomics and genomic features of Enterococcus avium IRMC1622a isolated from a clinical sample of hospitalized patient 从住院病人临床样本中分离出的肠球菌 IRMC1622a 的表型组学和基因组特征
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-30 DOI: 10.1016/j.jiph.2024.05.051
Reem AlJindan , Nehal Mahmoud , Doaa M. AlEraky , Noor B. Almandil , Sayed AbdulAzeez , J. Francis Borgio

Background

Enterococcus avium (E. avium) is a Gram-positive nosocomial pathogen that is commonly isolated from the alimentary tract. The objective of this functional genomics study was to identify the resistant genes by analyzing the genome of E. avium IRMC1622a, a type of bacteria found in feces collected from a patient at a Saudi Arabian tertiary hospital.

Methods

The bacterial strain IRMC1622a was identified by 16 S rRNA sequencing as Enterococcus sp. The resistance phenomics were performed using VITEK® 2, and morphological analysis was achieved using a scanning electron microscope (SEM). Finally, the whole bacterial genome of the bacterial strain IRMC1622a was subjected to sequencing during October 2023 using Oxford Nanopore long-read sequencing technology, and mining for resistant genes.

Results

The results of antimicrobial resistant phenomics indicated that the IRMC1622a strain was sensitive to all tested antimicrobial agents except for erythromycin, and the same result was confirmed by genomic analysis in addition to other classes of antibiotics. SEM showed E. avium IRMC1622a is ovoid shape, in single cells (L 1.2797 ± 0.1490 µm), in pairs (L 1.7333 ± 0.1054 µm), and in chains (L 2.44033 ± 0.1978 µm). The E. avium IRMC1622a genome has 14 (in CARD) antimicrobial resistance genes that were identified with several mechanisms of antimicrobial resistance, such as the efflux pump and conferring antibiotic resistance. The present study revealed that the E. avium IRMC1622a genome contains a high number of genes associated with virulence factors, and 14 matched pathogenic protein families and predicted as human pathogen (probability score 0.855). We report two (ISEnfa4 and ISEfa5) mobile genetic elements for the first time in the E. avium genome.

Conclusions

The study concludes that E. avium IRMC1622a is susceptible to all tested antibacterials except erythromycin. The IRMC1622a has 14 genes encoding antimicrobial resistance mechanisms, including the efflux pump and conferring antibiotic resistance. This could indicate a potential rise in E. avium resistance in healthcare facilities. These observations may raise concerns regarding E. avium resistance in healthcare. We need more research to understand the pathophysiology of E. avium, which leads to hospital-acquired infections.

背景阿维金单胞菌(E. avium)是一种革兰氏阳性的医院病原体,通常从消化道中分离出来。这项功能基因组学研究的目的是通过分析 E. avium IRMC1622a 的基因组来确定耐药基因,这种细菌是从沙特阿拉伯一家三甲医院收集的患者粪便中发现的。结果抗菌药耐药性表型组学结果表明,IRMC1622a 菌株对除红霉素外的所有测试抗菌药均敏感,而且除其他类抗生素外,基因组分析也证实了这一结果。扫描电镜显示,E. avium IRMC1622a呈卵圆形,单细胞(长 1.2797 ± 0.1490 µm)、成对(长 1.7333 ± 0.1054 µm)和成链(长 2.44033 ± 0.1978 µm)。E. avium IRMC1622a基因组有14个(CARD中)抗菌药耐药性基因,这些基因被鉴定出具有多种抗菌药耐药性机制,如外排泵和赋予抗生素耐药性。本研究发现,E. avium IRMC1622a 基因组中含有大量与毒力因子相关的基因,有 14 个符合致病蛋白家族并被预测为人类病原体(概率分数为 0.855)。我们首次在阿维菌的基因组中报告了两个(ISEnfa4 和 ISEfa5)移动遗传元件。结论该研究得出结论,阿维菌 IRMC1622a 对除红霉素以外的所有测试抗菌药物均敏感。IRMC1622a 有 14 个编码抗菌药耐药性机制的基因,包括外排泵和赋予抗生素耐药性的基因。这可能预示着医疗机构中阿维菌素耐药性的潜在上升。这些观察结果可能会引起人们对医疗机构中阿维菌耐药性的担忧。我们需要更多的研究来了解导致医院获得性感染的阿维菌病的病理生理学。
{"title":"Phenomics and genomic features of Enterococcus avium IRMC1622a isolated from a clinical sample of hospitalized patient","authors":"Reem AlJindan ,&nbsp;Nehal Mahmoud ,&nbsp;Doaa M. AlEraky ,&nbsp;Noor B. Almandil ,&nbsp;Sayed AbdulAzeez ,&nbsp;J. Francis Borgio","doi":"10.1016/j.jiph.2024.05.051","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.05.051","url":null,"abstract":"<div><h3>Background</h3><p><em>Enterococcus avium (E. avium)</em> is a Gram-positive nosocomial pathogen that is commonly isolated from the alimentary tract. The objective of this functional genomics study was to identify the resistant genes by analyzing the genome of <em>E. avium</em> IRMC1622a, a type of bacteria found in feces collected from a patient at a Saudi Arabian tertiary hospital.</p></div><div><h3>Methods</h3><p>The bacterial strain IRMC1622a was identified by <em>16 S rRNA</em> sequencing as <em>Enterococcus</em> sp. The resistance phenomics were performed using VITEK® 2, and morphological analysis was achieved using a scanning electron microscope (SEM). Finally, the whole bacterial genome of the bacterial strain IRMC1622a was subjected to sequencing during October 2023 using Oxford Nanopore long-read sequencing technology, and mining for resistant genes.</p></div><div><h3>Results</h3><p>The results of antimicrobial resistant phenomics indicated that the IRMC1622a strain was sensitive to all tested antimicrobial agents except for erythromycin, and the same result was confirmed by genomic analysis in addition to other classes of antibiotics. SEM showed <em>E. avium</em> IRMC1622a is ovoid shape, in single cells (L 1.2797 ± 0.1490 µm), in pairs (L 1.7333 ± 0.1054 µm), and in chains (L 2.44033 ± 0.1978 µm). The <em>E. avium</em> IRMC1622a genome has 14 (in CARD) antimicrobial resistance genes that were identified with several mechanisms of antimicrobial resistance, such as the efflux pump and conferring antibiotic resistance. The present study revealed that the <em>E. avium</em> IRMC1622a genome contains a high number of genes associated with virulence factors, and 14 matched pathogenic protein families and predicted as human pathogen (probability score 0.855). We report two (IS<em>Enfa4</em> and IS<em>Efa5</em>) mobile genetic elements for the first time in the <em>E. avium</em> genome.</p></div><div><h3>Conclusions</h3><p>The study concludes that <em>E. avium</em> IRMC1622a is susceptible to all tested antibacterials except erythromycin. The IRMC1622a has 14 genes encoding antimicrobial resistance mechanisms, including the efflux pump and conferring antibiotic resistance. This could indicate a potential rise in <em>E. avium</em> resistance in healthcare facilities. These observations may raise concerns regarding <em>E. avium</em> resistance in healthcare. We need more research to understand the pathophysiology of <em>E. avium</em>, which leads to hospital-acquired infections.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001977/pdfft?md5=ed21f311dee5042edddc8c9ad94b2fab&pid=1-s2.0-S1876034124001977-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141240427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endogenous bacterial endophthalmitis in an HIV patient with uncontrolled diabetes: A case of rare ocular complication 一名糖尿病未得到控制的艾滋病患者的内源性细菌性眼内炎:一例罕见的眼部并发症
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-30 DOI: 10.1016/j.jiph.2024.05.049
Yahya Ali Mohzari , Oweida Fahad AlDosary , Reem F. Bamogaddam , Munira AlHussaini , Hamad Al Alyami , Ahmad Alrashed , Ahmad Alamer

Endogenous bacterial endophthalmitis (EE) is an intraocular infection with a poor prognosis. Timely diagnosis and prompt treatment are crucial to prevent vision loss. In this communication, we describe a case of EE caused by Streptococcus pyogenes (Group A Streptococcus [GAS]) in an HIV-positive patient with poorly controlled type 2 diabetes mellitus (DM). A 60-year-old man with a history of HIV and poorly controlled type 2 diabetes, presented with progressive blurry vision, left eye pain, redness, and headache. EE was diagnosed based on the clinical presentation and gram stain analysis of blood culture. Treatment with vitreous tap, intravitreal, topical antibiotics, and systemic antibiotics significantly improved the patient's symptoms. The case highlights the rarity of GAS as a causative agent of EE, particularly in patients with risk factors such as HIV infection and DM.

内源性细菌性眼内炎(EE)是一种预后不良的眼内感染。及时诊断和及时治疗对防止视力丧失至关重要。在这篇通讯中,我们描述了一例由化脓性链球菌(A 组链球菌 [GAS])引起的 EE 病例,患者是一名 HIV 阳性且 2 型糖尿病(DM)控制不佳的患者。一名 60 岁的男性患者有艾滋病史,且 2 型糖尿病控制不佳,表现为进行性视力模糊、左眼疼痛、发红和头痛。根据临床表现和血液培养的革兰氏染色分析,确诊为 EE。经过玻璃体穿刺、玻璃体内注射、局部抗生素和全身抗生素治疗后,患者症状明显好转。该病例凸显了 GAS 作为 EE 病因的罕见性,尤其是在有 HIV 感染和糖尿病等危险因素的患者中。
{"title":"Endogenous bacterial endophthalmitis in an HIV patient with uncontrolled diabetes: A case of rare ocular complication","authors":"Yahya Ali Mohzari ,&nbsp;Oweida Fahad AlDosary ,&nbsp;Reem F. Bamogaddam ,&nbsp;Munira AlHussaini ,&nbsp;Hamad Al Alyami ,&nbsp;Ahmad Alrashed ,&nbsp;Ahmad Alamer","doi":"10.1016/j.jiph.2024.05.049","DOIUrl":"https://doi.org/10.1016/j.jiph.2024.05.049","url":null,"abstract":"<div><p>Endogenous bacterial endophthalmitis (EE) is an intraocular infection with a poor prognosis. Timely diagnosis and prompt treatment are crucial to prevent vision loss. In this communication, we describe a case of EE caused by <em>Streptococcus pyogenes</em> (Group A Streptococcus [GAS]) in an HIV-positive patient with poorly controlled type 2 diabetes mellitus (DM). A 60-year-old man with a history of HIV and poorly controlled type 2 diabetes, presented with progressive blurry vision, left eye pain, redness, and headache. EE was diagnosed based on the clinical presentation and gram stain analysis of blood culture. Treatment with vitreous tap, intravitreal, topical antibiotics, and systemic antibiotics significantly improved the patient's symptoms. The case highlights the rarity of GAS as a causative agent of EE, particularly in patients with risk factors such as HIV infection and DM.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001965/pdfft?md5=0c2cf1b73ea0f88ae6a459557aa20954&pid=1-s2.0-S1876034124001965-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141292301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential association between COVID-19 infections and the declining incidence of lung cancers COVID-19 感染与肺癌发病率下降之间的潜在联系。
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-27 DOI: 10.1016/j.jiph.2024.05.046
Josef Yayan, Diana Saleh, Karl-Josef Franke

Background

The COVID-19 pandemic has significantly impacted global health and prompted studies on its effects across various diseases. Recent data suggest a potential correlation between COVID-19 and a decrease in lung cancer incidence. This study examines the association between COVID-19 infection and changes in lung cancer cases.

Material and methods

We conducted a retrospective analysis of medical records from Clinic Lüdenscheid, Germany, from January 1, 2018, to December 31, 2021, comparing lung cancer cases before and during the pandemic. Demographic characteristics and cancer stages were also assessed.

Results

We evaluated 523 patients; 269 pre-COVID and 254 during COVID. While the overall number of cases declined, a significant increase in advanced stage cancers was noted during COVID (P = 0.04). The adjusted incidence rates showed a nuanced decrease from approximately 33 cases per 100,000 pre-COVID to 31 during COVID.

Conclusion

This retrospective study suggests a modest decline in lung cancer incidence and an increase in advanced stages during COVID. Further comparisons with national data indicate a similar trend across Germany, with a decrease of about 3 % in lung cancer diagnoses post-2020, highlighting potential pandemic impacts on cancer detection.

背景:COVID-19 大流行对全球健康产生了重大影响,并促使人们研究其对各种疾病的影响。最近的数据表明,COVID-19 与肺癌发病率下降之间可能存在关联。本研究探讨了 COVID-19 感染与肺癌病例变化之间的关联:我们对德国吕登沙伊德诊所 2018 年 1 月 1 日至 2021 年 12 月 31 日的医疗记录进行了回顾性分析,比较了大流行之前和期间的肺癌病例。此外,还对人口统计学特征和癌症分期进行了评估:我们对 523 名患者进行了评估,其中 269 人在 COVID 之前,254 人在 COVID 期间。虽然病例总数有所下降,但在 COVID 期间,晚期癌症病例显著增加(P = 0.04)。调整后的发病率出现了细微的下降,从 COVID 前的每 100,000 人约 33 例降至 COVID 期间的 31 例:这项回顾性研究表明,在 COVID 期间,肺癌发病率略有下降,晚期病例有所增加。与全国数据的进一步比较表明,整个德国的趋势相似,2020 年后肺癌诊断率将下降约 3%,这凸显了大流行对癌症检测的潜在影响。
{"title":"Potential association between COVID-19 infections and the declining incidence of lung cancers","authors":"Josef Yayan,&nbsp;Diana Saleh,&nbsp;Karl-Josef Franke","doi":"10.1016/j.jiph.2024.05.046","DOIUrl":"10.1016/j.jiph.2024.05.046","url":null,"abstract":"<div><h3>Background</h3><p>The COVID-19 pandemic has significantly impacted global health and prompted studies on its effects across various diseases. Recent data suggest a potential correlation between COVID-19 and a decrease in lung cancer incidence. This study examines the association between COVID-19 infection and changes in lung cancer cases.</p></div><div><h3>Material and methods</h3><p>We conducted a retrospective analysis of medical records from Clinic Lüdenscheid, Germany, from January 1, 2018, to December 31, 2021, comparing lung cancer cases before and during the pandemic. Demographic characteristics and cancer stages were also assessed.</p></div><div><h3>Results</h3><p>We evaluated 523 patients; 269 pre-COVID and 254 during COVID. While the overall number of cases declined, a significant increase in advanced stage cancers was noted during COVID (<em>P</em> = 0.04). The adjusted incidence rates showed a nuanced decrease from approximately 33 cases per 100,000 pre-COVID to 31 during COVID.</p></div><div><h3>Conclusion</h3><p>This retrospective study suggests a modest decline in lung cancer incidence and an increase in advanced stages during COVID. Further comparisons with national data indicate a similar trend across Germany, with a decrease of about 3 % in lung cancer diagnoses post-2020, highlighting potential pandemic impacts on cancer detection.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001862/pdfft?md5=70c20a611ef3df8f4fc6e4133e20f4bd&pid=1-s2.0-S1876034124001862-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment 雷米替韦在有或没有严重肾功能损害的 COVID-19 住院患者中的临床疗效和安全性
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-24 DOI: 10.1016/j.jiph.2024.05.048
Min-Chi Chang , Ping-Feng Wu , Yu-Chien Ho , Wen-Ying Lin , Chia-Ying Wu , Szu-Yu Liu , Chia-Jen Liu , Yi-Tsung Lin

Background

The use of remdesivir in patients with coronavirus disease 2019 (COVID-19) and severe renal impairment has been approved; however, limited clinical data exist. Accordingly, we aimed to compare outcomes and adverse events associated with remdesivir in hospitalized patients with COVID-19, with and without severe renal impairment.

Methods

Hospitalized patients with COVID-19 undergoing a 5-day remdesivir course at Taipei Veterans General Hospital from April 1 to July 31, 2022, were enrolled. Comparative analysis of outcomes and safety between patients with or without severe renal impairment (estimated glomerular filtration rate of < 30 mL/min per 1.73 m2) were conducted. Prognostic factors associated with 28-day mortality in patients with severe renal impairment were investigated using logistic regression analysis.

Results

A total of 671 hospitalized patients, including 132 patients with severe renal impairment, who received a 5-day course of remdesivir were analyzed. The 28-day mortality was higher in patients with severe renal impairment than in patients without severe renal impairment (15.2% vs. 7.8%). The proportion of patients with acute kidney injury (AKI) and deteriorated liver function after completing remdesivir therapy was similar between the patients with and without severe renal impairment, and the recovery rate of AKI was similar in both groups. The sequential organ failure assessment score was an independent factor associated with 28-day mortality in patients with severe renal impairment.

Conclusions

Remdesivir was well-tolerated in hospitalized patients with COVID-19, regardless of renal function. Our findings support the recent recommendation to administer remdesivir in patients with severe renal impairment.

背景已批准在患有冠状病毒病2019(COVID-19)和严重肾功能损害的患者中使用雷米替韦,但临床数据有限。因此,我们旨在比较有和无严重肾功能损害的 COVID-19 住院患者使用雷米替韦后的疗效和相关不良事件。方法 2022 年 4 月 1 日至 7 月 31 日,在台北荣民总医院住院的 COVID-19 患者接受了为期 5 天的雷米替韦疗程。对有或无严重肾功能损害(估计肾小球滤过率为< 30 mL/min per 1.73 m2)患者的预后和安全性进行了比较分析。结果 对接受雷米替韦 5 天疗程治疗的 671 名住院患者进行了分析,其中包括 132 名严重肾功能损害患者。与无严重肾功能损害的患者相比,严重肾功能损害患者的 28 天死亡率更高(15.2% 对 7.8%)。完成雷米替韦治疗后出现急性肾损伤(AKI)和肝功能恶化的患者比例在有严重肾损伤和无严重肾损伤的患者中相似,两组患者的AKI恢复率也相似。结论雷米替韦在COVID-19住院患者中耐受性良好,与肾功能无关。我们的研究结果支持最近提出的对严重肾功能损害患者使用雷米替韦的建议。
{"title":"Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment","authors":"Min-Chi Chang ,&nbsp;Ping-Feng Wu ,&nbsp;Yu-Chien Ho ,&nbsp;Wen-Ying Lin ,&nbsp;Chia-Ying Wu ,&nbsp;Szu-Yu Liu ,&nbsp;Chia-Jen Liu ,&nbsp;Yi-Tsung Lin","doi":"10.1016/j.jiph.2024.05.048","DOIUrl":"10.1016/j.jiph.2024.05.048","url":null,"abstract":"<div><h3>Background</h3><p>The use of remdesivir in patients with coronavirus disease 2019 (COVID-19) and severe renal impairment has been approved; however, limited clinical data exist. Accordingly, we aimed to compare outcomes and adverse events associated with remdesivir in hospitalized patients with COVID-19, with and without severe renal impairment.</p></div><div><h3>Methods</h3><p>Hospitalized patients with COVID-19 undergoing a 5-day remdesivir course at Taipei Veterans General Hospital from April 1 to July 31, 2022, were enrolled. Comparative analysis of outcomes and safety between patients with or without severe renal impairment (estimated glomerular filtration rate of &lt; 30 mL/min per 1.73 m<sup>2</sup>) were conducted. Prognostic factors associated with 28-day mortality in patients with severe renal impairment were investigated using logistic regression analysis.</p></div><div><h3>Results</h3><p>A total of 671 hospitalized patients, including 132 patients with severe renal impairment, who received a 5-day course of remdesivir were analyzed. The 28-day mortality was higher in patients with severe renal impairment than in patients without severe renal impairment (15.2% vs. 7.8%). The proportion of patients with acute kidney injury (AKI) and deteriorated liver function after completing remdesivir therapy was similar between the patients with and without severe renal impairment, and the recovery rate of AKI was similar in both groups. The sequential organ failure assessment score was an independent factor associated with 28-day mortality in patients with severe renal impairment.</p></div><div><h3>Conclusions</h3><p>Remdesivir was well-tolerated in hospitalized patients with COVID-19, regardless of renal function. Our findings support the recent recommendation to administer remdesivir in patients with severe renal impairment.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001874/pdfft?md5=945fcfc427f727e9ce721140f0adae67&pid=1-s2.0-S1876034124001874-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial stewardship programs in acute-care hospitals: A multicenter assessment of structure, process, and outcome indicators in Italy and Spain 急诊医院的抗菌药物管理计划:意大利和西班牙对结构、流程和结果指标的多中心评估
IF 6.7 3区 医学 Q1 Medicine Pub Date : 2024-05-24 DOI: 10.1016/j.jiph.2024.05.045
Giuseppina Lo Moro , Noemi Marengo , Alessandro Mara , José Ramón Paño Pardo , Sergi Hernandez , Ester Fusté , Miquel Pujol , Carla Maria Zotti , Enric Limón , Costanza Vicentini

Background

Antimicrobial stewardship (AMS) programs have been differently implemented across Europe. This study primarily aimed to compare AMS in two European regions. Secondarily, the study explored the COVID-19 pandemic impact on surrogate outcome indicators of AMS.

Methods

A retrospective observational study was conducted in Piedmont (Italy) and Catalonia (Spain). AMS programs were compared through structure and process indicators in 2021. Changes in surrogate outcome indicators (antimicrobial usage; alcohol-based sanitizer consumption; antimicrobial resistance, AMR) from 2017 to 2021 described the pandemic impact.

Results

Seventy-eight facilities provided structure and process indicators. Catalonia showed better structure scores (p < 0.001) and less dispersion in both indicators. The greatest areas to improve were accountability (Piedmont) and diversification of strategies (Catalonia). Overall, the regions reported consistent changes in outcome indicators. Antimicrobial usage decreased in 2020, returning to near-pre-pandemic levels in 2021. Alcohol-based sanitizer consumption surged in 2020, then dipped remaining above pre-pandemic levels. AMR trends were minimally affected.

Conclusions

The centralized approach of Catalonia ensured consistent attainment of quality objectives across all facilities, but it may limit facility-specific strategies. In Piedmont, accountability remain one of the most critical factors as in previous years. The pandemic did not substantially disrupt surrogate outcome measures of AMS. However, the data on AMR suggest that maintaining vigilance against this issue remains paramount.

背景抗菌药物管理(AMS)计划在欧洲各地的实施情况各不相同。本研究的主要目的是比较两个欧洲地区的抗菌药物管理计划。方法 在皮埃蒙特(意大利)和加泰罗尼亚(西班牙)开展了一项回顾性观察研究。通过 2021 年的结构和流程指标对 AMS 项目进行了比较。代用结果指标(抗菌药物使用量、酒精消毒剂消耗量、抗菌药物耐药性、AMR)从 2017 年到 2021 年的变化描述了大流行的影响。加泰罗尼亚的结构得分较高(p <0.001),两项指标的分散程度较低。最需要改进的方面是问责制(皮埃蒙特)和战略多样化(加泰罗尼亚)。总体而言,各地区报告的成果指标变化一致。2020 年抗菌剂使用量有所下降,2021 年恢复到接近大流行前的水平。酒精消毒剂的使用量在 2020 年激增,随后有所下降,但仍高于大流行前的水平。结论加泰罗尼亚的集中化方法确保了所有设施始终如一地实现质量目标,但可能会限制针对具体设施的策略。在皮埃蒙特,与往年一样,问责制仍然是最关键的因素之一。大流行并没有对急性呼吸系统综合症的代用结果指标产生重大影响。然而,有关 AMR 的数据表明,对这一问题保持警惕仍然至关重要。
{"title":"Antimicrobial stewardship programs in acute-care hospitals: A multicenter assessment of structure, process, and outcome indicators in Italy and Spain","authors":"Giuseppina Lo Moro ,&nbsp;Noemi Marengo ,&nbsp;Alessandro Mara ,&nbsp;José Ramón Paño Pardo ,&nbsp;Sergi Hernandez ,&nbsp;Ester Fusté ,&nbsp;Miquel Pujol ,&nbsp;Carla Maria Zotti ,&nbsp;Enric Limón ,&nbsp;Costanza Vicentini","doi":"10.1016/j.jiph.2024.05.045","DOIUrl":"10.1016/j.jiph.2024.05.045","url":null,"abstract":"<div><h3>Background</h3><p>Antimicrobial stewardship (AMS) programs have been differently implemented across Europe. This study primarily aimed to compare AMS in two European regions. Secondarily, the study explored the COVID-19 pandemic impact on surrogate outcome indicators of AMS.</p></div><div><h3>Methods</h3><p>A retrospective observational study was conducted in Piedmont (Italy) and Catalonia (Spain). AMS programs were compared through structure and process indicators in 2021. Changes in surrogate outcome indicators (antimicrobial usage; alcohol-based sanitizer consumption; antimicrobial resistance, AMR) from 2017 to 2021 described the pandemic impact.</p></div><div><h3>Results</h3><p>Seventy-eight facilities provided structure and process indicators. Catalonia showed better structure scores (p &lt; 0.001) and less dispersion in both indicators. The greatest areas to improve were accountability (Piedmont) and diversification of strategies (Catalonia). Overall, the regions reported consistent changes in outcome indicators. Antimicrobial usage decreased in 2020, returning to near-pre-pandemic levels in 2021. Alcohol-based sanitizer consumption surged in 2020, then dipped remaining above pre-pandemic levels. AMR trends were minimally affected.</p></div><div><h3>Conclusions</h3><p>The centralized approach of Catalonia ensured consistent attainment of quality objectives across all facilities, but it may limit facility-specific strategies. In Piedmont, accountability remain one of the most critical factors as in previous years. The pandemic did not substantially disrupt surrogate outcome measures of AMS. However, the data on AMR suggest that maintaining vigilance against this issue remains paramount.</p></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876034124001850/pdfft?md5=e05dfd88d6cf8fb049e5572aaecad642&pid=1-s2.0-S1876034124001850-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Infection and Public Health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1